Lyell Immunopharma News

Lyell Immunopharma | ARS: Annual Report to Security Holders

Apr 22 16:22 ET

Lyell Immunopharma | DEFA14A: Others

Apr 22 16:22 ET

Lyell Immunopharma | DEF 14A: Definitive information statements

Apr 22 16:17 ET

Lyell Immunopharma | S-3: Registration statement for specified transactions by certain issuers

Feb 29 13:35 ET

Lyell Immunopharma | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans

Feb 29 13:35 ET

Lyell Immunopharma | 10-K: Annual report

Feb 28 22:28 ET

Lyell Immunopharma | 8-K: Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2023

Feb 28 16:15 ET

Lyell Immunopharma | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-ARCH Venture Fund IX, L.P.(14.5%),ARCH Venture Fund IX Overage, L.P.(14.5%), etc.

Feb 14 15:24 ET

Lyell Immunopharma | 4: Statement of changes in beneficial ownership of securities-Officer Lang Matthew

Feb 13 20:31 ET

Lyell Immunopharma | 4: Statement of changes in beneficial ownership of securities-Officer Hill Stephen J.

Feb 13 20:26 ET

Lyell Immunopharma | 4: Statement of changes in beneficial ownership of securities-Officer Lee Gary K.

Feb 13 20:26 ET

Lyell Immunopharma | 4: Statement of changes in beneficial ownership of securities-Officer Newton Charles W.

Feb 13 20:21 ET

Lyell Immunopharma | 4: Statement of changes in beneficial ownership of securities-Officer Seely Lynn

Feb 13 20:21 ET

Lyell Immunopharma | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-The Vanguard Group(5.40%)

Feb 13 17:52 ET

Lyell Immunopharma | SC 13G: Statement of acquisition of beneficial ownership by individuals-BlackRock, Inc.(5.7%)

Jan 29 17:37 ET

Lyell Immunopharma | 4: Statement of changes in beneficial ownership of securities-Chief Financial Officer Newton Charles W.

Nov 20, 2023 20:55 ET

Lyell Immunopharma | 4: Statement of changes in beneficial ownership of securities-Officer Lee Gary K.

Nov 20, 2023 20:54 ET

Lyell Immunopharma | 4: Statement of changes in beneficial ownership of securities-Officer Seely Lynn

Nov 20, 2023 20:53 ET

Lyell Immunopharma | 4: Statement of changes in beneficial ownership of securities-Officer Hill Stephen J.

Nov 20, 2023 20:52 ET

Lyell Immunopharma | 8-K: Current report

Nov 20, 2023 16:26 ET